Latest Content

First Patient Dosed in Trial of [212Pb]VMT01 for Metastatic Melanoma

March 30th 2025, 6:00pm

By Ryan Scott

The first patient has been dosed with [212Pb]VMT01 in a phase 1/2a trial evaluating the safety of the agent in patients with melanoma.

What Patients With Kidney Cancer Need to Know From ASCO GU

March 30th 2025, 2:00pm

By Alex Biese

Article

There were a number of notable developments for patients with kidney cancer at the symposium, Dr. Emre Yekedüz explained.

Research Shines Light on Disparities Across Breast Cancer Care

March 29th 2025, 2:00pm

By Dr. Regina Hampton

Video

Dr. Regina Hampton discusses key factors contributing to this disparity, and how healthcare systems can address these challenges.

FDA Approves Imfinzi Therapy in Muscle Invasive Bladder Cancer

March 28th 2025, 9:11pm

By Ryan Scott

Article

The FDA approved neoadjuvant Imfinzi, gemcitabine and cisplatin, followed by adjuvant Imfinzi after radical cystectomy in muscle invasive bladder cancer.

Life Goes On, Even With Breast Cancer

March 28th 2025, 8:00pm

By Laura Yeager

Article

I reflect on how cancer has brought out resilience and support in others, even as I struggled with my own battle, and wish others strength in their journeys.

Why Physical Therapy Should Begin at the Time of a Cancer Diagnosis

March 28th 2025, 7:11pm

By Leslie Waltke

Video

CURE spoke with Leslie Waltke about the importance of physical therapy during a cancer journey.

FDA Expands Pluvicto Indication in Prostate Cancer Subset

March 28th 2025, 5:13pm

By Spencer Feldman

Article

FDA expands Pluvicto indication to adults with PSMA+ metastatic castration-resistant prostate cancer previously treated with androgen receptor inhibitors.

SON-1010 Generates Safe Results in Advanced Sarcoma

March 28th 2025, 4:00pm

By Alex Biese

Article

A phase 1 trial has reported positive safety findings of SON-1010 among patients with advanced leiomyosarcoma (LMS) or liposarcoma (LPS).

Solnerstotug Demonstrates Early Efficacy in PD-L1 Resistant Tumors

March 28th 2025, 3:00pm

By Spencer Feldman

Article

Favorable initial results from a phase 1/2 trial of solnerstotug in PD-L1–resistant tumors showed a 14% response rate and 62% disease control rate.

Childhood Cancer Survivors May Experience Sooner Aging-Related Disease

March 28th 2025, 1:00pm

By Alex Biese

Article

Researchers have found childhood cancer survivors are at risk of experiencing onset of aging-related disease 17.7 years sooner than the general population.

Kidney Cancer Awareness Month Highlights Advocacy and Early Detection

March 27th 2025, 9:00pm

By Ryan Scott

Article

March is Kidney Cancer Awareness Month, highlighting the disease, early detection and and patient advocacy, with voices like Sid Sadler raising awareness.